Target OA pain* the way nothing else does, and keep dogs at their owners’ sides

  • Galliprant is a first-in-class non-COX-inhibiting analgesic1
  • It works differently from COX-inhibiting NSAIDs, specifically blocking the EP4 receptor – a key mediator of OA pain1 but does not interfere with homeostatic mechanisms mediated through other prostanoid receptors2

GALLIPRANT Group BottleBoxPill 60mg UK 02-11-2018 360x310

Video: Watch Galliprant’s innovative mode of action

Sign in or register for MyElanco to watch other videos and see more from the experts.

Galliprant treats OA pain from first diagnosis to stop the pain and let the fun carry on

  • Galliprant delivers proven pain relief, and its treatment effect is comparable to traditional NSAIDs2,3
  • In a field study of client-owned dogs, Galliprant treatment resulted in statistically significant improvements in pain interference and pain severity scores compared to placebo on days 7, 14, 21 and 28 (primary study endpoint), P ≤0.05 for all2

Video: Duncan Lascelles, Professor of Small Animal Surgery and Pain Management at North Carolina State University, discusses the clinical evidence for use of Galliprant for osteoarthritis in dogs.

Sign in or register for MyElanco to watch other videos and see more from the experts.

Galliprant can be used for as long as needed to protect all the special moments to come*†

  • Well-tolerated when used once daily2,4
  • Galliprant was well-tolerated over 9 months at doses equivalent to 15x the target dose in the target animal safety study4
  • No treatment was stopped or dogs removed from the study due to adverse events4
  • Suitable for dogs as young as 9 months of age
  • Simple, once-daily, chewable tablet
  • Most dogs can be dosed once a day with a whole or half tablet
Galliprant dosing table

Latest news & more about Galliprant

Galliprant voted best new veterinary product of the year 2019!
Incorporate Galliprant into your canine OA protocol today! Get full details, videos and resources by signing up to MyElanco (for those in the UK). For those in Ireland, please complete this form.

Video: Voted for by vets, Galliprant has won the Veterinary Marketing Association’s award for the best new veterinary product 2019.

Sign in or register for MyElanco to watch other videos and see more from the experts.

†As field studies were limited to 28 days, longer-term treatment should be considered carefully and regular monitoring undertaken by the vet.


References:

  1. Kirkby Shaw, K, et al. Vet Med Sci. 2016;2:3-9.
  2. Rausch-Derra LC, et al. J Vet Intern Med. 2016;30:756-763.
  3. CVMP Assessment Report for Galliprant.
  4. Rausch-Derra LC, et al. Am J Vet Res. 2015;76(10):853-859.

Name of the veterinary medicinal product: Galliprant 20 mg, 60 mg, and 100 mg tablets for dogs. * Indication: Galliprant is indicated for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Side effects, precautions, warnings and contraindications: Refer to the product packaging and leaflets for information about side effects, precautions, warnings and contraindications. Storage: Do not store above 30°C. Any half tablets should be stored in the bottle. In order to avoid any accidental ingestion, store tablets out of reach of animals.


Galliprant contains grapiprant. Legal category POM-V (UK) POM (IE).


Further information is available from the Summary of Product Characteristics or datasheet. Advice should always be sought from the medicine prescriber. Information on this veterinary medicinal product is available on the website of the European Medicines Agency https://www.ema.europa.eu. For further information call Elanco Animal Health on +44(0)1256 353131 or write to: Elanco UK AH limited, Form 2, Bartley Way, Bartley Wood Business Park, Hook, RG27 9XA.


Use medicines responsibly www.noah.co.uk/responsible (UK); www.apha.ie (IE).


© Elanco or its affiliates. PM-UK-20-1059 January 2021